Tamsulosin 0.4
Pro Research Analysisby 
Searched over 200M research papers for "tamsulosin 0.4"
Efficacy and Safety of Tamsulosin 0.4 mg in Treating Benign Prostatic Hyperplasia (BPH)
Introduction to Tamsulosin 0.4 mg
Tamsulosin is a selective alpha-1A and alpha-1D adrenoceptor antagonist primarily used to treat lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). The 0.4 mg once-daily dosage is particularly noted for its efficacy and safety profile in improving urinary flow and reducing symptoms of BPH.
Improvement in Urinary Flow and Symptom Relief
Maximum Urinary Flow Rate (Qmax)
Multiple studies have demonstrated that tamsulosin 0.4 mg significantly improves the maximum urinary flow rate (Qmax) in patients with BPH. In a meta-analysis of two European studies, tamsulosin increased Qmax by 1.6 ml/s (16%) compared to 0.6 ml/s (6%) in the placebo group (p = 0.002). Another study confirmed these findings, showing a 1.4 mL/s (13.1%) improvement in Qmax with tamsulosin compared to 0.4 mL/s (3.8%) with placebo (P = 0.028). Additionally, a dose-ranging study found that tamsulosin 0.4 mg produced a 22.6% improvement in Qmax, significantly higher than placebo (-0.9%).
Symptom Score Reduction
Tamsulosin 0.4 mg has also been effective in reducing the total symptom score in patients with BPH. The European Tamsulosin Study Group reported a 35.1% reduction in the Boyarsky symptom score with tamsulosin compared to a 25.5% reduction with placebo (p = 0.002). Another study showed a 35.8% reduction in total symptom score with tamsulosin, significantly better than the 23.7% reduction with placebo (P = 0.002). In a phase III trial, tamsulosin 0.4 mg led to a 25% reduction in the American Urological Association symptom score, outperforming placebo (p = 0.01).
Safety and Tolerability
Adverse Events
Tamsulosin 0.4 mg is generally well-tolerated, with a safety profile comparable to placebo. The incidence of drug-related adverse events was similar between tamsulosin and placebo groups (13% vs. 12%, p = 0.802). Common adverse events include dizziness and abnormal ejaculation, but these are not significantly different from placebo. A study focusing on older and younger patients found no significant differences in adverse events between age groups, further supporting the drug's safety.
Cardiovascular Safety
Tamsulosin 0.4 mg does not significantly affect blood pressure or heart rate, making it a safe option for patients with or without hypertension. Studies have shown minimal changes in blood pressure or pulse rate in both hypertensive and normotensive patients treated with tamsulosin compared to placebo . This is particularly advantageous over other alpha-1 adrenoceptor antagonists, which often require dose titration and can cause hypotensive effects.
Impact on Sexual Function
While tamsulosin 0.4 mg has been associated with abnormal ejaculation, this side effect is generally not perceived as a major problem by patients and is reversible upon drug withdrawal. Importantly, tamsulosin does not significantly affect libido or impotence compared to placebo or alfuzosin. In fact, some studies have reported an improvement in total sexual function score with tamsulosin compared to placebo (p = 0.042).
Conclusion
Tamsulosin 0.4 mg once daily is a well-tolerated and effective treatment for improving urinary flow and reducing symptoms in patients with BPH. Its safety profile, particularly regarding cardiovascular effects and sexual function, makes it a valuable therapeutic option. The drug's efficacy in both short-term and long-term use further solidifies its role in managing LUTS associated with BPH.
Sources and full results
Most relevant research papers on this topic